Sapient Capital LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, Holdings Channel.com reports. The fund bought 10,146 shares of the biotechnology company’s stock, valued at approximately $978,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Montag A & Associates Inc. acquired a new position in Sarepta Therapeutics in the third quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the last quarter. CWM LLC lifted its stake in shares of Sarepta Therapeutics by 178.7% in the 4th quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 370 shares during the period. Fifth Third Bancorp boosted its position in shares of Sarepta Therapeutics by 1,215.8% in the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 924 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $165,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 2.3 %

Sarepta Therapeutics stock traded up $3.03 during midday trading on Friday, reaching $133.66. The stock had a trading volume of 1,196,284 shares, compared to its average volume of 876,130. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.45 and a current ratio of 4.05. The firm’s fifty day simple moving average is $125.63 and its 200-day simple moving average is $110.76. The stock has a market capitalization of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.44) earnings per share. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on SRPT shares. Needham & Company LLC reissued a “buy” rating and issued a $166.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. Royal Bank of Canada lifted their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Evercore ISI upped their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research note on Tuesday, February 20th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a report on Friday. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $160.60.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock valued at $2,739,419 in the last three months. 7.40% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.